Pinteon Therapeutics

Pinteon Therapeutics Overview

Founded 2014
Founded
Status Private
Employees 6
Employees
Latest Deal Type Series A
Latest Deal Amount $17M
Latest Deal Amount
Investors 1

Pinteon Therapeutics General Information

Description

Developer of novel antibody designed to maintain brain health of the patients. The company's antibody interrupts the spread of toxic tau and protect and preserve brain function in patients who suffers from neurodegenerative disease, enabling researchers to normalize aberrant disease processes and improve patient outcomes in these high unmet medical need indications.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Primary Office
  • 1188 Centre Street
  • Newton Centre
  • Newton, MA 02459
  • United States
+1 (917) 000-0000

Pinteon Therapeutics Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pinteon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 31-Oct-2019 $17M 0000 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 17-Aug-2017 0000 0000 000.00 Completed Generating Revenue

Pinteon Therapeutics Cap Table

To view Pinteon Therapeutics‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000

Pinteon Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Martin Jefson Ph.D Chief Executive Officer
Michael Ahlijanian Ph.D Chief Scientific Officer
Larry Altstiel MD Chief Medical Officer

1 Former Executive

Pinteon Therapeutics Board Members (3)

Name Representing Role Since
Jason Dinges Ph.D Morningside Group Board Member 000 0000
Jeffrey Ives Ph.D Self Chairman 000 0000
Westley Nolin Ph.D Self Board Member 000 0000

Pinteon Therapeutics Investors (1)

To view Pinteon Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Morningside Group Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial